[2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure].

[1]  V. Ho,et al.  Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia , 2016, American journal of hematology.

[2]  A. Ganser,et al.  Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation , 2015, British journal of haematology.

[3]  H. Acar.  A Pediatric Myelodysplastic Syndrome with Chromosome 5q Deletion , 2015 .

[4]  U. Platzbecker,et al.  Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate? , 2015, Current Hematologic Malignancy Reports.

[5]  J. Cortes,et al.  Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  G. Mufti,et al.  Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy? , 2014, Clinical lymphoma, myeloma & leukemia.

[7]  A. Ganser,et al.  Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study , 2014, European journal of haematology.

[8]  M. Cazzola,et al.  Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. , 2014, Blood.

[9]  U. Platzbecker.  Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights. , 2013, Hematology. American Society of Hematology. Education Program.

[10]  G. Leone,et al.  Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups , 2013, Haematologica.

[11]  N. Kröger,et al.  Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT , 2013, Bone Marrow Transplantation.

[12]  Stefano Guidi,et al.  Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome , 2013, American journal of hematology.

[13]  L. Arenillas,et al.  Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. , 2013, Blood.

[14]  H. Deeg,et al.  Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how? , 2012, Blood reviews.

[15]  W. Hiddemann,et al.  Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. , 2012, The Lancet. Oncology.

[16]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[17]  H. Deeg,et al.  Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. , 2012, Blood.

[18]  E. Estey,et al.  Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  Y. Lee,et al.  Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome , 2012, Bone Marrow Transplantation.

[20]  A. Órfão,et al.  Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group , 2012, Leukemia.

[21]  M. Cazzola,et al.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.

[22]  J. Astermark,et al.  Quality of life, physical function and MRI T2* in elderly low‐risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions , 2011, European journal of haematology.

[23]  B. Esterni,et al.  Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[25]  F. Atem,et al.  Activity of azacitidine in chronic myelomonocytic leukemia , 2011, Cancer.

[26]  G. Mufti,et al.  Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes , 2011, Cancer.

[27]  H. Deeg,et al.  Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  R. Gale,et al.  SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS , 2011, Bone Marrow Transplantation.

[29]  B. Ebert,et al.  Unraveling the molecular pathophysiology of myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Ganser,et al.  Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  N. Young,et al.  Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  C. Cutler.  Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome. , 2010, Hematology. American Society of Hematology. Education Program.

[33]  G. Mufti,et al.  Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. , 2010, Critical reviews in oncology/hematology.

[34]  W. Hofmann,et al.  Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. , 2010, Leukemia research.

[35]  G. Mufti,et al.  Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine * , 2010, European journal of haematology.

[36]  A. Stamatoullas,et al.  Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). , 2010, Leukemia research.

[37]  G. Mufti,et al.  Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C , 2010, British journal of haematology.

[38]  M. Rondoni,et al.  Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q‐ deletion , 2010, British journal of haematology.

[39]  H. Dombret,et al.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Perkins,et al.  5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation , 2010, Bone Marrow Transplantation.

[41]  J. Issa,et al.  Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities , 2009, Cancer.

[42]  D. Cella,et al.  Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). , 2009, Blood.

[43]  N. Kröger,et al.  Outcome of allo-SCT for chronic myelomonocytic leukemia , 2009, Bone Marrow Transplantation.

[44]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[45]  H. Deeg,et al.  The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[46]  M. Cazzola,et al.  Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P. Emanuel.  Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia , 2008, Leukemia.

[48]  John Barrett,et al.  Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  M. Maris,et al.  Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[50]  H. Dombret,et al.  Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. , 2008, Blood.

[51]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[52]  N. Gattermann.  Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. , 2007, Leukemia research.

[53]  H. Leitch.  Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. , 2007, Leukemia research.

[54]  J. Astermark,et al.  Negative Effect of DNA Hypermethylation on the Outcome of Intensive Chemotherapy in Older Patients with High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia following Myelodysplastic Syndrome , 2007, Clinical Cancer Research.

[55]  M. Cazzola,et al.  Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study , 2007, European journal of haematology.

[56]  G. Ehninger,et al.  Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem-cell transplantation. , 2007, Blood.

[57]  U. Germing,et al.  Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes , 2007, Cancer.

[58]  G. Mufti,et al.  Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin , 2007, Leukemia.

[59]  U. Germing,et al.  Myelodysplastic syndromes in patients younger than age 50. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  P. Greenberg,et al.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.

[61]  R. Larson,et al.  Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[63]  L. Mannone,et al.  High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study , 2006, British journal of haematology.

[64]  E. Neufeld.  Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. , 2006, Blood.

[65]  M. Gobbi,et al.  Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study , 2006, Annals of Hematology.

[66]  I. Dybedal,et al.  Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. , 2005, Blood.

[67]  H. Dombret,et al.  Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. , 2004, Blood.

[68]  H. Heimpel,et al.  A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes , 2004, Leukemia.

[69]  A. Barrett,et al.  A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. , 2003, Blood.

[70]  G. Gahrton,et al.  No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease , 2003, Leukemia.

[71]  I. Dybedal,et al.  A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life , 2003, British journal of haematology.

[72]  G. Mufti,et al.  A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low‐risk’ myelodysplasia , 2003, British journal of haematology.

[73]  Peter A. Jones,et al.  Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. , 2002, Blood.

[74]  John P Klein,et al.  Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. , 2002, Blood.

[75]  N. Young,et al.  HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. , 2002, Blood.

[76]  M. Cappellini,et al.  The safety and effectiveness of deferiprone in a large‐scale, 3‐year study in Italian patients , 2002, British journal of haematology.

[77]  Terry L. Smith,et al.  Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. , 2002, Blood.

[78]  J. Porter.  Practical management of iron overload , 2001, British journal of haematology.

[79]  A. Hagemeijer,et al.  Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. , 2001, Blood.

[80]  G. Ehninger,et al.  New strategies for prophylactic platelet transfusion in patients with hematologic diseases. , 2001, The oncologist.

[81]  W. Hiddemann,et al.  Phase II study of combination human recombinant GM‐CSF with intermediate‐dose cytarabine and mitoxantrone chemotherapy in patients with high‐risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): An Eastern Cooperative Oncology Group Study , 2001, American journal of hematology.

[82]  Benz,et al.  Low‐dose melphalan induces favourable responses in elderly patients with high‐risk myelodysplastic syndromes or secondary acute myeloid leukaemia , 2000, British journal of haematology.

[83]  F. Ferrara,et al.  Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation , 1999, Annals of Hematology.

[84]  P. Sonneveld,et al.  A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group , 1998, Leukemia.

[85]  M. Lazzarino,et al.  Randomized clinical study comparing aggressive chemotherapy with or without G‐CSF support for high‐risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS , 1998, British journal of haematology.

[86]  N. Young,et al.  Antithymocyte globulin for patients with myelodysplastic syndrome , 1997, British journal of haematology.

[87]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[88]  Margaret A Farquhar,et al.  Consensus Conference on Platelet Transfusion , 1997 .

[89]  K. Kojima,et al.  Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. , 1996, Leukemia.

[90]  H. Zwierzina,et al.  Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). , 1995, Leukemia.

[91]  H. Johnsen,et al.  Priming and treatment with molgramostim (rhGM‐CSF) in adult high‐risk acute myeloid leukemia during induction chemotherapy: a prospective, randomized pilot study , 1995, European journal of haematology.

[92]  G. Gahrton,et al.  A predictive model for the clinical response to low dose ara‐C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia , 1992, British journal of haematology.

[93]  P. Morel,et al.  Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy , 1991, British journal of haematology.

[94]  B. Cheson,et al.  Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience. , 1987, Seminars in oncology.

[95]  Francesco Onida,et al.  Faculty of 1000 evaluation for Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. , 2012 .

[96]  R. Arceci.  Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias , 2011 .

[97]  H. Leitch.  Controversies surrounding iron chelation therapy for MDS. , 2011, Blood reviews.

[98]  L. Vickars,et al.  Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron? , 2009, Hematology. American Society of Hematology. Education Program.

[99]  J. Ritz,et al.  A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[100]  M. Tormo,et al.  Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. , 2006, Cancer.

[101]  B. Johansson,et al.  Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. , 2006, Haematologica.

[102]  J. Winter,et al.  The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study , 2005, Annals of Hematology.

[103]  T. Robak,et al.  Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. , 2003, Neoplasma.

[104]  E. Estey,et al.  Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes , 2003, Leukemia.

[105]  C. Tinelli,et al.  Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes. , 1997, Haematologica.

[106]  B. Pégourié,et al.  A Randomized Trial of Hydroxyurea Versus VP 16 in Adult Chronic Myelomonocytic Leukemia , 2022 .